Paris La Défense, France – 5th October 2026
SGD Pharma, a global market leader in pharmaceutical glass primary packaging and a pioneer in sustainability and decarbonization, will showcase its expanded portfolio of molded and tubular glass packaging solutions at CPHI Milan, from 6 to 8 October 2026, at booth 11F17.
The company will introduce three innovations designed to address evolving pharmaceutical industry needs: MySterinity Nasal, Ready-to-Use (RTU) tubular vials, and MySealian.
MySterinity Nasal: Ready-to-Use Solutions for Nasal Drug Delivery
SGD Pharma will debut MySterinity Nasal, a new range of molded glass vials extending its established Sterinity approach.*
Developed for the growing high-value nasal drug delivery market, this solution addresses increasing microbiological requirements, particularly as biologic therapies continue to expand.
MySterinity Nasal offers pharmaceutical companies greater flexibility, enhanced quality and safety, and improved Total Cost of Ownership (TCO).
The Type I U-Save nasal vials are available with different preparation levels, including washing, depyrogenation and sterilization. They are suitable for systemic therapies, central nervous system (CNS) therapies, and vaccines.
Ready-to-Use Tubular Vials for Sensitive Parenteral Drugs
SGD Pharma is also launching its Ready-to-Use (RTU) tubular vials, designed for sensitive, high-value parenteral medicines.
Washed, depyrogenated and sterilized, these vials support pharmaceutical companies operating in aseptic fill-finish environments, where quality, safety and efficiency are essential.
The new tubular RTU vials will be manufactured at SGD Pharma's Felino facility in Italy, following the acquisition of Alphial. The site features an ISO 5 manufacturing environment.
By expanding its RTU portfolio, SGD Pharma aims to offer customers faster delivery, improved TCO and the convenience of sourcing a complete range of Type I RTU vials from a single supplier.
MySealian: Expanding Access to Advanced Glass Treatment
SGD Pharma is introducing MySealian, a new GMP-compliant subcontracting service that makes its Sealian treatment available for customers' and partners' existing glass vials.
This service enables glass manufacturers, pharmaceutical companies and original equipment manufacturers (OEMs) to benefit from SGD Pharma's internal glass treatment technology without requiring capital investment.
Sealian creates a protective barrier coating inside glass vials, helping preserve the integrity of sensitive therapeutic formulations.
Its enhanced hydrophobic properties reduce the adhesion of high-viscosity products to the internal glass surface. This supports better product visibility, easier inspection and reduced product waste.
In addition, Sealian will now be available as a treatment option for SGD Pharma's new tubular vial solutions, further expanding the company's molded and tubular glass packaging portfolio.
Combining Pharmaceutical Glass Innovation and Sustainability
Commenting on the portfolio expansion, Olivier Rousseau, CEO of SGD Pharma, stated:
“One year after the acquisition of Alphial, SGD Pharma is well positioned to address the evolving challenges of the pharmaceutical industry, offering innovative products and solutions across both molded and tubular glass primary packaging. We are particularly proud that these innovations are developed within a comprehensive ESG framework, ensuring that sustainability considerations are embedded from the very outset of every project.”
The new solutions reflect SGD Pharma's commitment to developing innovative pharmaceutical glass packaging while integrating sustainability considerations from the earliest stages of product development.
SGD Pharma partners with SG EZ-fill® to offer washed, depyrogenated and sterilized Type I molded glass vials. These solutions are designed to meet pharmaceutical industry requirements, accelerate time to market and reduce Total Cost of Ownership through improved quality and flexibility.